Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History PRTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics PRTA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Prothena Corporation plc

PRTA
Current price
6.57 USD +0.02 USD (+0.31%)
Last closed 6.52 USD
ISIN USG728001086
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 346 376 736 USD
Yield for 12 month -70.60 %
1Y
3Y
5Y
10Y
15Y
PRTA
21.11.2021 - 28.11.2021

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland. Address: 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

24.29 USD

P/E Ratio

Dividend Yield

Financials PRTA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures PRTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+135 157 000 USD

Last Year

+91 370 000 USD

Current Quarter

+2 828 000 USD

Last Quarter

+2 123 000 USD

Current Year

+131 572 000 USD

Last Year

-129 201 000 USD

Current Quarter

+2 828 000 USD

Last Quarter

+1 210 000 USD
EBITDA -137 712 992 USD
Operating Margin TTM -2 318.99 %
Price to Earnings
Return On Assets TTM -15.49 %
PEG Ratio 0.80
Return On Equity TTM -23.46 %
Wall Street Target Price 24.29 USD
Revenue TTM 137 935 008 USD
Book Value 8.13 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 5 556.00 %
Dividend Yield
Gross Profit TTM -71 281 000 USD
Earnings per share -2.05 USD
Diluted Eps TTM -2.05 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -79.94 %

Stock Valuation PRTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 64.10
Enterprise Value Revenue 2.82
Price Sales TTM 2.51
Enterprise Value EBITDA -3.58
Price Book MRQ 0.78

Technical Indicators PRTA

For 52 Weeks

4.32 USD 25.42 USD
50 Day MA 6.60 USD
Shares Short Prior Month 4 414 727
200 Day MA 12.86 USD
Short Ratio 2.24
Shares Short 4 655 763
Short Percent 16.27 %